0.03
0.03 (0%)
As of Oct 21, 2024
Gritstone Bio, Inc. [GRTS]
Source:
Company Overview
Gritstone Bio, Inc is a clinical-stage biotechnology company focused on combining immunological insights with proprietary technologies and capabilities to develop next-generation vaccines.
| Country | United States |
| Headquarters | emeryville, california |
| Phone Number | (510) 871-6100 |
| Industry | manufacturing |
| CEO | Andrew Allen, M.D., Ph.D. |
| Website | www.gritstonebio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.9 |
| Operating Profit | $-27.6 |
| Net Income | $-23.4 |
| Net Cash | $-13.7 |
Profit Ratios
| Gross Margin | $0.9 |
| Operating Margin | -2,995.4 |
| Profit as % of Revenues | -3.9% |
| Profit as % of Assets | -14.6% |
| Profit as % of Stockholder Equity | -105.4% |
Management Effectiveness
| Return on Equity | -105.4% |
| Return on Assets | -16.4% |
| Turnover Ratio | 0.6% |
| EBITA | $-27.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $142.5 |
| Total Liabilities | $120.4 |
| Operating Cash Flow | $-60.4 |
| Investing Cash Flow | $11.4 |
| Financing Cash Flow | $35.3 |
